Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufangkushen Ningjiao is a Traditional Chinese Medicine (TCM) gel formulation developed by Guiyang Xintian Pharmaceutical for the treatment of bacterial vaginosis and other gynecological inflammations. It primarily contains extracts from Sophora flavescens (Kushen) and Sanguisorba officinalis (Di Yu). The mechanism of action involves the antimicrobial and anti-inflammatory properties of alkaloids like matrine and oxymatrine, which inhibit the growth of pathogens such as Gardnerella vaginalis and Trichomonas vaginalis while helping to restore the vaginal microecosystem. It is applied topically (intravaginally) and is approved in China for various forms of vaginitis and cervicitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufangkushen ningjiao.